Wolverine Trading’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $14.3M | Sell |
19,630
-20,386
| -51% | -$15.2M | 0.01% | 750 |
|
|
2025
Q2 | $31M | Sell |
40,016
-14,984
| -27% | -$11.6M | 0.03% | 340 |
|
|
2025
Q1 | $45.2M | Sell |
55,000
-13,458
| -20% | -$11.2M | 0.05% | 228 |
|
|
2024
Q4 | $53M | Sell |
68,458
-51,713
| -43% | -$42.8M | 0.05% | 222 |
|
|
2024
Q3 | $105M | Sell |
120,171
-42,382
| -26% | -$38.1M | 0.11% | 103 |
|
|
2024
Q2 | $147M | Buy |
162,553
+116,084
| +250% | +$92.9M | 0.16% | 71 |
|
|
2024
Q1 | $36.2M | Buy |
46,469
+31,273
| +206% | +$22.3M | 0.04% | 265 |
|
|
2023
Q4 | $8.86M | Buy |
15,196
+12,906
| +564% | +$7.53M | 0.01% | 783 |
|
|
2023
Q3 | $1.23M | Sell |
2,290
-11,980
| -84% | -$6.17M | ﹤0.01% | 1960 |
|
|
2023
Q2 | $6.63M | Sell |
14,270
-33,718
| -70% | -$14.1M | 0.01% | 766 |
|
|
2023
Q1 | $16.3M | Sell |
47,988
-108,714
| -69% | -$36.7M | 0.03% | 394 |
|
|
2022
Q4 | $57.3M | Buy |
+156,702
| New | +$55.6M | 0.09% | 177 |
|
|
2022
Q3 | – | Sell |
-1,609
| Closed | -$520K | – | 5006 |
|
|
2022
Q2 | $520K | Buy |
1,609
+821
| +104% | +$246K | ﹤0.01% | 2507 |
|
|
2022
Q1 | $228K | Sell |
788
-43,623
| -98% | -$11.2M | ﹤0.01% | 4242 |
|
|
2021
Q4 | $12.3M | Buy |
44,411
+10,147
| +30% | +$2.57M | 0.01% | 632 |
|
|
2021
Q3 | $7.89M | Buy |
34,264
+11,519
| +51% | +$2.84M | 0.01% | 968 |
|
|
2021
Q2 | $5.22M | Sell |
22,745
-3,273
| -13% | -$657K | 0.01% | 1100 |
|
|
2021
Q1 | $4.83M | Buy |
26,018
+6,591
| +34% | +$1.29M | 0.01% | 1144 |
|
|
2020
Q4 | $3.25M | Sell |
19,427
-6,708
| -26% | -$1M | 0.01% | 1359 |
|
|
2020
Q3 | $3.82M | Sell |
26,135
-1,816
| -6% | -$281K | 0.01% | 1017 |
|
|
2020
Q2 | $4.55M | Buy |
+27,951
| New | +$4.29M | 0.01% | 866 |
|
|
2020
Q1 | – | Sell |
-75,935
| Closed | -$10.4M | – | 4974 |
|
|
2019
Q4 | $9.97M | Buy |
75,935
+24,266
| +47% | +$2.81M | 0.02% | 673 |
|
|
2019
Q3 | $5.81M | Buy |
51,669
+49,444
| +2,222% | +$5.5M | 0.02% | 788 |
|
|
2019
Q2 | $247K | Buy |
2,225
+157
| +8% | +$18.5K | ﹤0.01% | 3484 |
|
|
2019
Q1 | $268K | Sell |
2,068
-47,525
| -96% | -$5.78M | ﹤0.01% | 3497 |
|
|
2018
Q4 | $5.66M | Sell |
49,593
-16,118
| -25% | -$1.8M | 0.02% | 732 |
|
|
2018
Q3 | $7.05M | Buy |
65,711
+53,726
| +448% | +$5.37M | 0.02% | 754 |
|
|
2018
Q2 | $927K | Hold |
11,985
| – | – | ﹤0.01% | 2340 |
|
|
2018
Q1 | $927K | Sell |
11,985
-45,931
| -79% | -$3.7M | ﹤0.01% | 2340 |
|
|
2017
Q4 | $4.89M | Buy |
+57,916
| New | +$4.93M | 0.02% | 874 |
|
|
2017
Q3 | – | Sell |
-26,571
| Closed | -$2.2M | – | 4759 |
|
|
2017
Q2 | $2.2M | Buy |
26,571
+19,607
| +282% | +$1.6M | 0.01% | 1176 |
|
|
2017
Q1 | $590K | Sell |
6,964
-49,821
| -88% | -$3.99M | ﹤0.01% | 2201 |
|
|
2016
Q4 | $4.18M | Sell |
56,785
-36,012
| -39% | -$2.68M | 0.02% | 840 |
|
|
2016
Q3 | $7.4M | Buy |
92,797
+31,019
| +50% | +$2.48M | 0.03% | 556 |
|
|
2016
Q2 | $4.83M | Buy |
+61,778
| New | +$4.65M | 0.03% | 633 |
|
Other funds holding LLY
Wolverine Trading's LLY Position: Q3 2025 in Review
Wolverine Trading reduced its Eli Lilly (LLY) stake by 51% in Q3 2025, selling an estimated $15.2M and leaving 19,630 shares worth $14.3M. The position accounts for 0.01% of the portfolio, ranked #750.
Wolverine Trading first reported a position in LLY in Q2 2016 and has held it in 35 quarters since. The position peaked at $147M in Q2 2024. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.
- Wolverine Trading held 19,630 shares of Eli Lilly worth $14.3M as of Q3 2025.
- Wolverine Trading sold 20,386 Eli Lilly shares in Q3 2025, an estimated $15.2M.
- Eli Lilly made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #750 holding.
- Wolverine Trading first reported a position in Eli Lilly in Q2 2016 and has held it in 35 quarters since.
- Wolverine Trading's Eli Lilly position peaked at $147M in Q2 2024.
- 3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.